• 1
    Alergológica-2005. 2006. Factores epidemiológicos, clínicos y socioeconómicos de las enfermedades alérgicas en España en 2005. Sociedad Española de Alergología e Inmunología Clínica & Schering-Plough, editores. Madrid, Egraf SA.
  • 2
    Bousquet, J., P. G. Burney, T. Zuberbier, P. V. Cauwenberge, C. A. Akdis, C. Bindslev-Jensen, S. Bonini, W. J. Fokkens, F. Kauffmann, M. L Kowalski, et al. 2009. GA2LEN (Global Allergy and Asthma Networks) address the allergy and asthma epidemic. Allergy 64:969977.
  • 3
    Till, S. J., J. N. Francis, K. Nouri-Aria, et al. 2004. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 113(6):10251034.
  • 4
    Akdis, C. A., K. Blaser, 2000. Mechanisms of allergen-specific immunotherapy. Allergy 55(6):522530.
  • 5
    Akdis, C. A., M. Blesken, M. Akdis, B. Wuthrich, K. Blaser, 1998. Role of interleukin-10 in specific immunotherapy. J. Clin. Invest. 102(1):98106.
  • 6
    Hawrylowicz, C. M., A. O'Garra, 2005. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat. Rev. Immunol. 5:271283.
  • 7
    Norman, P. S. 2004. Immunotherapy: 1994–2004. J. Allergy Clin. Immunol. 113:10131023.
  • 8
    Cox, L., H. Nelson, R. Lockey, 2001. Allergen immunotherapy: A practical parameter third update. J. Allergy Clin. Immunol. 1(suppl):S1S55.
  • 9
    Marsh, D. G., L. M. Lichenstein, D. H. Campbell, 1970. Studies on ‘allergoids’ prepared from naturally occurring allergens. Immunology. 18(5):705722.
  • 10
    Henmar, H., G. Lund, L. Lund, P. A. Petersen, A. Würtzen, 2008. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin. Exp. Immunol. 153(3):316323.
  • 11
    Casanovas, M., E. Fernandez-Caldas, R. Alamar, A. Basomba, 2005. Comparative study of tolerance between unmodified and high doses of chemically modified allergen vaccines of Dermatophagoides pteronyssinus. Int. Arch. Allergy Immunol. 137:211218.
  • 12
    Cirkovic, T. D., M. N. Bukilica, M. D. Gavrovic, Z. M. Vujcic, S. Petrovic, R. M. Jankov, 1999. Physicochemical and immunologic characterization of low-molecular-weight allergoids of Dactylisglomerata pollen proteins. Allergy. 54:128134.
  • 13
    Kahlert, H., O. Cromwell, H. Fiebig, 2003. Measurement of basophil-activating capacity of grass pollen allergens, allergoids and hypoallergenic recombinant derivatives by flow cytometry using anti-CD203c. Clin. Exp. Allergy. 33:12661272.
  • 14
    Baldrick, P., D. Richardson, S. R. Woroniecki, et al. 2007. Pollinex® Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of ragweed pollen allergy. J. Appl. Toxicol. 27(4):399409.
  • 15
    Baldrick, P., D. Richardson, A. W. Wheeler, 2002. Review of L-tyrosine confirming its safe human use as an adjuvant. J. Appl. Toxicol. 22(5):333344.
  • 16
    Varney, V. A., K. Tabbah, G. Mavroleon, et al. 2003. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: A double-blind, randomized, placebo-controlled trial. Clin. Exp. Allergy. 33:10761082.
  • 17
    Tabar, A. I., L. Fernandez-Tavora, R. Alonso, et al. 2004. Tolerance of a cluster schedule with a house dust mite extract quantified in mass units: Multicenter study. J. Investig. Allergol. Clin. Immunol. 14:193197.
  • 18
    Garcia-Robaina, J. C., I. Sanchez, F. de la Torre, et al. 2006. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo- controlled study. J. Allergy Clin. Immunol. 118:10261032.
  • 19
    Zhang, L., C. Wang, D. Han, X. Wang, Y. Zhao, J. Liu, 2009. Comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int. Arch. Allergy Immunol. 148:161169.
  • 20
    Dordal M.T., M. Lluch-Bernal, M.C. Sanchez, C. Rondon, A. Navarro, J. Montoro, V. Matheu, M.D. Ibanez, B. Fernandez-Parra, I. Davila, et al. 2011. Allergen-specific nasal provocation testing: review by the rhinoconjunctivitis committee of the Spanish Society of Allergy and Clinical Immunology. J. Investig. Allergol. Clin. Immunol. 21(1):112.
  • 21
    Atkinson, M. J., A. Sinha, S. L. Hass, S. S. Colman, R. N. Kumar, M. Brod, C. R. Rowland, 2004. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual. Life Outcomes. 2:12.
  • 22
    Trujols, J., I. Iraurgi, N. Siñol, M. J. Portella, V. Pérez, J. Pérez de Los Cobos, 2012. Satisfaction with methadone as a medication: psyc24 hometric properties of the Spanish version of the treatment satisfaction questionnaire for medication. J. Clin. PsycholPharmacol. 32(1):6974.
  • 23
    Shedden, A. 2005. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis. Treat Respir. Med. 4(6):439446.
  • 24
    Teixeira, R. U., C. E. Zappelini, F. S. Alves, E. A. da Costa, 2011. Peak nasal inspiratory flow evaluation as an objective method of measuring nasal airflow. Braz. J. Otorhinolaryngol. 77(4):473480.
  • 25
    Larché, M., C. A. Akdis, R. Valenta, 2006. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6:761771.
  • 26
    Cady, C. T., M. S. Powell, R. J. Harbeck, P. C. Giclas, J. R. Murphy, R. K. Katial, R. W. Weber, P. M. Hogarth, S. Johnson, E. Bonvini, et al. 2010. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcγRIIA and FcγRIIB. Immunol. Lett. 130(1–2):5765.